Citi Remains a Sell on Novavax (NVAX)
In a report released on January 5, from Citi maintained a Sell rating on Novavax, with a price target of $6.00.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
In a report released yesterday, Bank of America Securities also maintained a Sell rating on the stock with a $6.00 price target.
Based on Novavax’s latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $70.45 million and a GAAP net loss of $202.38 million. In comparison, last year the company earned a revenue of $84.51 million and had a GAAP net loss of $121.3 million
Read More on NVAX:
Disclaimer & DisclosureReport an Issue
- Vaccine committee considers changes to childhood schedule, NY Times reports
- MRNA, NVAX, BNTX: Here’s What Triggered a Sell-off in Major Vaccine Stocks Today
- Prasad email a headwind for vaccine manufacturers, says BofA
- Video: Vaccine makers slide following report of leaked memo from FDA’s Prasad
- Morning Movers: Synopsys leaps following Nvidia investment
This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.